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A B S T R A C T
The Neuronal Ceroid Lipofuscinoses (NCL), otherwise known as Batten disease, are a group of neurodegenerative
diseases caused by mutations in 13 known genes. All except one NCL is autosomal recessive in inheritance, with
similar aetiology and characterised by the accumulation of autofluorescent storage material in the lysosomes of
cells. Age of onset and the rate of progression vary between the NCLs. They are collectively one of the most
common lysosomal storage diseases, but the enigma remains of how genetically distinct diseases result in such
remarkably similar pathogenesis. Much has been learnt from cellular studies about the function of the proteins
encoded by the affected genes. Such research has utilised primitive unicellular models such as yeast and amoeba
containing gene orthologues, cells derived from naturally occurring (sheep) and genetically engineered (mouse)
animal models or patient-derived cells. Most recently, patient-derived induced pluripotent stem cell (iPSC) lines
have been differentiated into neural cell-types to study molecular pathogenesis in the cells most profoundly
affected by disease. Here, we review how cell models have informed much of the biochemical understanding of
the NCLs and how more complex models are being used to further this understanding and potentially act as
platforms for therapeutic efficacy studies in the future.
1. Yeast models
Yeast models have been regarded as an exceptional experimental
model system for all eukaryotic biology and carry many advantages to
elucidating complex biological systems in the modern era [1,2]. Uti-
lised for many decades, they possess all the classical eukaryotic orga-
nelles such as mitochondria, endoplasmic reticulum, vacuoles
(equivalent to lysosomes), and Golgi apparatus, allowing significant
insights into the mechanics and molecular cell biology of processes such
as cell division, metabolism, trafficking, and autophagy [3].
There has been extensive research to understand both the budding
yeast Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces
pombe, especially following the sequencing of their DNA in 1996 and
2002 respectively [4,5]. Their genomes were revealed in exceptional
detail, which has led to a robust quantitative analysis of both the
transcriptome and proteome profiles [6,7] as well as the development
of techniques, that have allowed characterisations of the regulatory
process and responses to environmental conditions [6]. In-silico tech-
niques have also been utilised to predict and identify domains [8], in-
cluding functionality. Additionally, both models have been used to
develop metabolic profiles [9] as well as predict protein-protein inter-
action networks [10,11]. Impressively all this data can be accessed
through their respective comprehensive open access genome databases,
yeastgenome.org and pombase.org [12,13]. Furthermore, the synergy
between valuable gene deletion libraries [14,15], robotic technologies
and a wide range of functional genomic tools, provide a significantly
robust platform to facilitate research in disease areas including neuro-
degeneration that affects fundamental cellular processes [16].
Both S. cerevisiae and Sz. pombe have been used to study the un-
derlying cause of some neuronal ceroid lipofuscinoses (NCLs). The
genes CLN3, CLN10/CTSD and CLN12/ATP13A2 [17], are conserved in
both yeasts, with CLN1 also in Sz. pombe [18]. To date, most work using
S. cerevisiae and Sz. pombe as models has focused on the orthologue of
CLN3 (BTN1 and btn1 respectively), which like CLN3, encode func-
tionally ill-defined transmembrane proteins.
1.1. CLN3
Research carried out in both yeasts has been reviewed extensively
[19], and will be summarised here. Within S. cerevisiae, BTN1 is known
to localise to the vacuole and Golgi, with a role in the homeostasis of
vacuolar morphology, cellular pH, storage and transport of amino acids
[20–27]. Similarly, in Sz. pombe Btn1 plays a far-reaching role in traf-
ficking to the vacuole, regulation of vacuolar size and pH, Golgi
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morphology, cell morphology, cell polarity, cytoskeleton, temperature
sensitivity, and osmotic homeostasis [28–33].
Work in fission yeast has inferred that proteins carrying pathogenic
mutations in btn1 can retain different aspects of function [32]. Most
relevant to juvenile CLN3 disease is the 1Kb deletion, which accounts
for 81% of pathogenic mutations found in patients' [34], that results in
a number of alternative transcripts [31]. A mutant protein equivalent to
one of these transcripts in Sz. pombe exhibited partial functionality and
was able to prevent some defects associated with complete loss of btn1,
such as vacuolar size [31]. Other missense mutations within the lu-
minal-facing domains cause significant effects on Btn1 function, most
notably those affecting the amphipathic helix [32]. Whether there is a
gain of function for some mutant CLN3 proteins is still under debate
and is important in the context of the development of therapies for
CLN3 disease and identification of therapeutic targets.
Genetic interactions are a good way of elucidating possible func-
tions and identification of therapeutic targets [35]. A known genetic
interaction between BTN1 and SDO1, an orthologue of Shwachman-
Bodian-Diamond syndrome (SBDS) in humans, was explored in S. cer-
evisiae using two-hybrid protein interactions, co-immunoprecipitation
and co-localization [36]. SDO1 is a guanine nucleotide exchange factor
(GEF) for ribosome assembly protein 1 (RIA1), another protein involved
in ribosomal maturation predominantly located within the cytoplasm
[37]. Absence of SDO1 leads to misregulation of BTN1 and a decrease in
the ability of V-ATPase to pump protons but also made the vacuole
more acidic. Although no direct physical interaction has been found
between BTN1 and V-ATPase, it has been suggested that BTN1 nega-
tively regulates ATP hydrolysis. It is unlikely that SDO1 and BTN1 di-
rectly interact with each other within the ribosomal maturation
pathway. However, a link between CLN3 and RNA metabolism was
suggested from work with a Drosophila model with enhanced CLN3
expression [38], with the suggestion that Sdo1p influences expression
of BTN1 through a ribosomal monitoring network that affects vacuolar
function and/or homeostasis. There has been increasing interest in the
involvement of the ribosomal pathway in neurodegeneration, either
through ribosomal stress granules [39], ribosomal stalling [40] or
mRNA homeostasis [41].
High-throughput screening has helped in the understanding of global
changes in the Sz. pombe model for CLN3 disease, through investigating
both the metabolome and genetic circuitry following the loss of Btn1
function [42,43]. Cells lacking Btn1 showed an increased glycolytic flux
and TCA cycle, and the heat sensitivity phenotype was rescued via sup-
plementation of glycolytic substrates, suggesting an adaptive response
change through the glycolysis pathway [43]. Bond et al. took this
adaptive change a step further, demonstrating a link between btn1 and a
conserved key signalling hub, the mTOR pathway [42]. The mTOR
pathway is a highly conserved signalling network that coordinates mul-
tiple cellular functions from environmental cues [44]. It plays a funda-
mental role in cellular behaviour and physiology, particularly quiescence
and longevity which are defective in btn1Δ cells [42,44]. Modulating
TORC1 function genetically or via pharmacological inhibition was able to
rescue all defects observed in the Sz. pombe btn1Δ model. This was also
true following activation of the cell wall integrity (CWI) pathway by
increasing the level of expression of rho1, reflecting the crosstalk be-
tween these two important pathways through Btn1 that may be inferred
for CLN3 [42]. This finding is increasingly relevant as mTOR is emerging
as a regulator of many neurological functions, such as circuit formation,
neural control of feeding and neuronal development [45] as well as to
the NCLs [46]. Deletion of mTORC1 or mTORC2 leads to reduced neuron
size and early death [44]. Intriguingly, hyperactivation of the mTORC1
pathway, is a hallmark of Tuberous Sclerosis (TSC) in patients as well
Tsc1 or Tsc2 knockout mouse models, that present with a range of neu-
rological disorders including epilepsy, relevant to NCL pathology
[47,48]. Both Tsc1/2 and Rhb1 (orthologue of Rheb) are conserved in
Sz. pombe, but have not yet been fully investigated in relation to btn1.
However, Tsc1/2 and Rheb are not conserved in S. cerevisiae which may
contribute to some of the mTOR associated differences between these
models of disease.
Abnormal protein trafficking and membrane dynamics are a hall-
mark in many neurodegenerative diseases such as Parkinson's,
Alzheimer's, Huntington's disease, as well as CLN3 disease [49–51].
First studied in Drosophila and mammalian systems, it was demon-
strated that overexpression of CLN3 causes aggregation of Hook1, a
regulator of endocytosis [52]. In S. cerevisiae, BTN2 was assigned as a
Hook1 orthologue [52] and was upregulated in cells that lack BTN1
[22]. Like Hook1, BTN2 was also shown to interact with SNARE com-
plexes, binding with v-SNARE SNC1 [53]. Upon deletion of BTN2, re-
trieval of YIF1 transport protein from late endosomes to the Golgi ap-
paratus was blocked. Similarly, BTN1 has been shown to regulate Golgi
morphology via modulation of SNARE protein SED5 itself phosphory-
lated by YCK3 [22,54]. Golgi disruption is also observed in Sz. pombe
upon the loss of btn1, with defects in Golgi morphology and location,
which has been suggested to lead to dysregulation of the cell cycle and
aberrant protein sorting of the vacuole hydrolase carboxypeptidase-Y
[33]. In addition, Sz. pombe had defects in the polarisation of sterol
domains, leading to loss of Myo1 localisation including defective for-
mation of F-actin patches and disruption of the endocytic pathway [29].
Correct Golgi and sorting function are vital in both metabolism and
distribution of lipid-bound membrane proteins. In S. cerevisiae BTN1
has a role in phospholipid distribution [55]. Absence of BTN1 leads to a
decrease in phosphatidylethanolamine (PtdEtn) and phosphatidylserine
(a precursor to PtdEtn) in the mitochondria and vacuolar membranes.
BTN1Δ cells given ethanolamine (Etn) supplement did not rescue the
PtdEtn concentrations and became toxic at higher doses. Since there
was no observation of PtdEtn accumulation in the ER, it implies a
dysfunctional Kennedy pathway [56] through the lack of substrate in-
corporation [55]. Therefore, the array of cellular phenotypes associated
with the lack of BTN1, and by extrapolation CLN3, could be the con-
sequence of altered phospholipid dynamics. Dobzinski et al. also ob-
served links with TOR signalling pathways and the processing of Golgi
proteins to vacuoles for degradation [57]. Inactivation of TOR under
starvation causes Golgi-quality-control (GQC) substrates to be re-
cognised by the vacuole protein machinery when ubiquitinated,
through the mediation of the defective-for-SREBP-cleavage complex
(DSC). Since the DSC complex in Sz. pombe promotes both ubiquitina-
tion and proteasome cleavage, it would be interesting to investigate a
connection with MVB protein sorting pathway. The authors suggest that
GQC substrate delivery upon starvation response may be a general pre-
autophagic response essential for cell survival or quiescence from up-
regulation of MVB-VPS pathways.
The relevance of the regulatory link between BTN2 and BTN1 is yet
not been fully elucidated. However the identification a third protein
that is a negative regulator of BTN2, BTN3 (yeast orthologue of a
human mitochondrial complex 1 deficiency gene) within the cellular
stress response and prion curing, raises many interesting questions
[58,59]. Current understanding is that BTN3 and SNC1 control BTN2
localisation and function. The observed inhibitory effects of prion
curing suggested that BTN3 downregulates protein trafficking and prion
aggregation from BTN2-mediated URE3, which may prove crucial
during the onset of mitochondrial complex 1 deficiency and Batten
disease in humans. BTN3 competes with SNC1 for BTN2's binding site,
sequestering it from its substrates [58]. Equally, BTN3 has been shown
to bind with ENT3 and ENT5 epsin proteins in late endosomes. This
suggested that BTN3 regulates endosomal sorting function of adaptor
proteins, BTN2, ENT3 and ENT5. Although one could argue that BTN2/
3 will not help identify the function of BTN1/CLN3, these observations
imply that the main pathway in Batten disease pathogenesis might be
linked to defects in the endosomal recycling of proteins involved in
vesicular fusion or to a yet to be identified prion-like substrate [60].
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1.2. CLN10
CLN10 (Cathepsin D) has functional orthologues in both S. cerevisiae
and Sz. pombe, PEP4 [61] and Sxa1 [62], respectively. The PEP4 model
is well characterised, and in recent years it has become apparent that
PEP4 is not solely a vacuolar degrader, which may offer insights into
other dysfunctional pathways in CLN10 mutations [63]. In S. cerevisiae
PEP4 affects gene expression through formation of the SAGA-like (Spt-
Ada-Gen5 acetyltransferase) or SLIK complex, having both an activa-
tion and inhibitory effect on genes [64,65]. PEP4 has also been shown
to influence chronological ageing through anti-apoptotic and anti-ne-
crotic processes. Intriguingly, delaying cell death is dependent on the
PEP4's catalytic active state while the necrotic and survival activity in
quiescent cells is conferred by PEP4's inactive state and is independent
of PEP4's catalytic activation [66]. Additionally, overexpression of
PEP4 was beneficial in a Parkinson's disease (PD) yeast model, de-
creasing the accumulation of α-synuclein, that would normally trigger
cell death by acidification [67]. PEP4 equalised pH homeostasis and
vacuolar proteolytic functions, decreasing α-synuclein aggregates. Un-
expectedly, this mechanism of action was dependent on functional
calcineurin signalling leading to correct trafficking of PEP4 [67].
1.3. CLN12
The identification of CLN12 (ATP13A2) in a rare case of Juvenile
NCL reminds of the relevance of other yeast models in NCLs and neu-
rodegenerative disease [17,68]. CLN12 is part of the superfamily of
ATPases transporting cations across cell membranes and is located on
the late endosomal/lysosome with emerging evidence of it being a
critical regulator of lysosomal function [69–72]. Loss of function mu-
tations in ATP13A2 is the leading cause of Kufor-Rakeb syndrome
(KRS), a rare form of early Parkinsonism [69]. CLN12 has an orthologue
in S. cerevisiae, YPK9. Although the molecular function and regulation
of CLN12/YPK9 remains unclear, cells deleted for this gene were ob-
served to have increased sensitivity to Cd2+, Mn2+, Ni2+ and Se2+
toxicity [73].
Similarly to PEP4, overexpression of YPK9 was observed to reduce
the accumulation of α-synuclein, a notable pathology in Parkinson's
disease (PD) and also observed in CLN3 disease models [74,75]. This
could infer an intrinsic link between the CLN12 and CLN3 patients who
also exhibit Parkinson's-like movement disorder [76]. Chesi et al.
characterised the YPK9 network, using a genome-wide study and con-
firmed than YPK9 is essential for manganese homeostasis. Utilising this
aspect, they observed YPK9 interacts with many proteins involved in
trafficking and manganese homeostasis [75].
In Sz. pombe CLN12/ATP13A2 has at least two homologues, cta5 and
SPCC1672.11c. Both are thought to encode for p-type ATPase trans-
porters, with Cat5 also functioning at a homeostatic regulator for Ca2+
and Mn2+ [77]. Intriguingly, both yeast models of CLN12 suggest in
part CLN12 can act as a Mn2+ regulator; conversely, it is known that
manganese is a risk factor for developing PD or PD-like syndrome,
implying the importance of manganese homeostasis in both Batten and
Parkinson's diseases [78].
2. Dictyostelium discoideum
The social amoeba has proven to be an excellent model organism to
research neurodegenerative diseases, including NCL genes, (reviewed
extensively in McLaren et al.) [79,80]. Dictyostelium encodes for 11 of
the 13 known genes linked to NCL. This makes Dictyostelium an at-
tractively simple model system to elucidate the function of NCL pro-
teins [81] and provide new tools to explore NCL disease. Mutations in
CLN2(TPP1) cause a late infantile form of NCL in CLN2 disease [76].
CLN2 is a serine protease that impacts fluidic phase endocytosis and
autophagy [82]. In Dictyostelium, six genes share similarities with CLN2,
and these are tpp1A-F [83]. Loss of tpp1A in Dictyostelium through
homologous recombination leads to a decrease in overall Tpp1 activity
and accumulation of storage material in cells that are starved [84].
Also, tpp1A−/− cells are impaired in growth and viability when con-
tinuously grown in axenic autophagy-stimulating media (ASM) [82,84].
This suggested that Tpp1A is required for proper autophagic response
under starvation conditions and is consistent with what was seen in
patient fibroblasts which have reduced autophagosome formation [82].
Stumpf et al. have recently studied two other TPP1 genes, tpp1B and
tpp1F. Tpp1B/F is thought to bind to the Golgi pH regulator (GPHR)
[83], an anion channel that regulates the morphology of both the Golgi
complex and the ER [85,86]. The localisation of Tpp1F in the ER, Golgi
complex, V-ATPase-positive vesicles and the binding of GPHR provide
new insight into the potential implications of CLN2 binding to GPHR in
human cell lines [83].
The Dictyostelium homolog of CLN3 is cln3. Cln3 is also a trans-
membrane protein and localised predominantly to the contractile va-
cuole system but also the Golgi complex and endocytic pathway, con-
sistent with other NCL models [87–89]. Cells lacking cln3 display a
variety of phenotypes during growth phase, including defects in cyto-
kinesis and osmoregulation as well as increased cell proliferation
[87,90]. During early development, cln3−/− cells show delayed
streaming and aggregation, impaired protein secretion and reduced
adhesion [87–89].
Unlike yeast models, Dictyostelium also has a functional orthologue
of CLN5 [81]. Mutations in CLN5 cause late infantile CLN5 disease [76].
In mammals, CLN5 is localised to the lysosome as well as being secreted
[91,92]. Highlighting the conserved nature of the NCL pathways, cells
lacking cln5 in Dictyostelium also accumulate autofluorescent storage
material [93]. The Cln5 interactome in Dictyostelium reveals that it in-
teracts with a range of proteins including lysosomal enzymes, proteases
and most notably includes other NCL proteins like TppB/Cln2, CtsD/
Cln10 and CtsF/Cln13, in addition to proteins linked with Cln3 function
such as quorum-sensing protein AprA and CadA, a calcium-dependent
cell-cell adhesion protein [92]. This suggests that there is indeed an
interconnectome between NCL genes, that have yet to be fully eluci-
dated.
3. Mouse cell models
3.1. Cerebellar granule cells
Cerebellar granule cells (CGCs) have long been recognised as being
a ubiquitously occurring within the mammalian brain [94]. First iso-
lated from murine models for cell culture in the 1970s, the dissociation
and growth of cerebellar granule cells have expedited the under-
standing of neuronal functionality in both wild-type and a disease-
based context [95]. Several murine models recapitulating multiple CLN
mutations have been produced from labs worldwide. From these
models, CGCs can be isolated as primary cells or immortalised to study
the molecular biology of disease. In vitro experiments using primary and
immortalised CGCs from Cln3, Cln6 and Cln7 mouse models have been
informative in better understanding NCL neuropathology.
There have been multiple Cln3 mouse models produced. Mitchison
et al. first described a Cln3Δex1–6 knockout murine model in 1999, fol-
lowed by Katz et al. generating the Cln3–/– knockout model and a
Cln3LacZ β-galactosidase reporter system being produced later [96–98].
A knock-in Cln3 mouse model produced by the Cotman lab re-
capitulates the 1 Kb intragenic deletion that is the most common in-
herited mutation in patients' with juvenile CLN3 disease [99]. The re-
sulting deletion removes exons 7 and 8 resulting in a protein that is
predicted to be out of frame after 153 amino acid residues – with 28
unconventional amino acids existing at the C-terminus, although al-
ternative splice variants bring the transcript back into frame. Previous
studies provide conflicting perspectives as to the residual or null
function of any CLN protein produced by mutated transcripts, or if the
transcripts are even translated at all [31,100–102]. That said, analysis
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of the Cln3Δex7/8 homozygote mice revealed an absence of exon 7 and 8
transcription as well as variant transcripts which also lack exon 5 or
retention of introns 1, 10 or 11 [103], suggesting alternative splicing
leads to variant Cln3 proteins being produced that are lacking different
portions. Therefore, the isolation and immortalisation of CGCs from
Cln3Δex7/8 murine models represented a foundation for insight into the
pathomechanism of neuronal cell death in Cln3Δex7/8 mice.
Fossale et al. were the first to demonstrate an archetypal NCL
phenotype within an immortalised CGC line isolated from Cln3Δex7/8
mice [49]. CGCs from the mutated mice (CbCln3Δex7/8) exhibit ab-
normalities in both mitochondrial and lysosomal size, distribution and
function as well as the hallmark accumulation of ATPase subunit c,
alongside reduced ATP levels and apoptosis. The Cotman lab also went
on to produce an immortalised CGC line from Cln6 knockout mice
(CbCln6nclf/nclf). They observed phenotypic similarities between the
Cln3 and Cln6 mutated CGC lines but divergent transcriptomic profiling
implying distinct functions in neurons converging on the same pathway
(s) [104].
Primary CGCs cultured from the CbCln3Δex7/8 knock-in mice de-
monstrate an altered sensitivity and excitotoxicity in both AMPA &
NMDA-type glutamate receptors in vitro. Abnormal cerebellar gluta-
mate receptor function may result in motor deficits. Seven week old
Cln3Δex7/8 knock-in mice were subsequently demonstrated to display a
reduction in motor co-ordination – presenting both AMPA and NMDA
glutamate receptor function as a potential therapeutic target
[102,105,106].
In 2019, the Storch lab produced the first immortalised neuronal
CGC line from Cln7 knockout mice [107]. Several phenotypic ab-
normalities were described in relation to late endosome/lysosomal
morphology, movement and distribution within CGCs. However, there
was no conclusive evidence of defective autophagy in Cln7−/− cells.
From this, it was speculated that CLN7 might function in nutrient
sensing and mTOR complex assembly. Moreover, it was suggested that
the accumulation of protein aggregates in the brains of murine models
might be a consequence of reduced axonal lysosomal migration. Yet,
more work needs to be undertaken for the exact neuronal function of
the CLN7 protein to be understood.
Finn et al., also highlights how mice with different genetic back-
grounds may contribute to potential differences in phenotypes.
Specifically, changes to glutamate receptor expression and ex-
citotoxicity differed in cells isolated from mice of different genetic
backgrounds, and this could therefore also influence how the receptor is
dysregulated in a disease context [102].
3.2. Embryonic fibroblasts
Isolated between E12.5 and E17 into gestation, mouse embryonic
fibroblasts (MEF) are relatively easy to culture and amplify for ap-
proximately 5–7 passages. There are a limited number of studies uti-
lising MEFs isolated from Cln3 null mice. However, in 2011, Getty et al.
observed cytoskeletal, and migration defects in Cln3−/−MEFs; myosin-
IIB distribution in Cln3 null cells was elongated indicating cytoskeletal
abnormalities [108]. Wavre-Shapton et al. showed that MEFs isolated
from Cln3Δex1–6 have disorganised membranes and reduced LAMP1
membrane recruitment [109].
In 2016, Brandenstein et al. isolated MEFs from Cln7Δex2 mice and
immortalised them employing lentiviral overexpression of the onco-
protein SV40 large T antigen [110]. Pulse-chase experiments in these
Cln7Δex2 MEFs revealed unaltered expression/maturation of cathepsin
proteins (proteases found in the lysosome), implying no lysosomal
acidification defect in Cln7 Δex2 MEFs [110]. These data contrast with in
vivo studies and data obtained from cultured neurons from Cln3Δex7/8
[49] and Cln1 [111], which both have impaired trafficking and altered
maturation of lysosomal enzymes. However, a lack of consistency in
phenotype could be due to the cell-type evaluated rather than disease.
A recent study described a role for Cln7 in lipid metabolism in
lysosomes in immortalised MEF cultures. In 2018, Danyukova et al.
observed functional pathology in the Cln7Δex2 immortalised MEFs; the
ability to adapt to starvation was impaired, and mTORC1 activity was
defective. Furthermore, an increase in perinuclear accumulation of
enlarged lysosomes was noted [46]. The group also performed SILAC-
based quantitative mass spectrometry analysis that revealed a sig-
nificantly different enzyme profile in the lysosomes of wild-type (WT)
and Cln7 KO MEFs. Notably, the soluble enzyme Cln5 (linked to late
infantile NCL disorder) was significantly reduced in the Cln7 KO lyso-
somes. This study is the first of its kind to describe the lysosomal pro-
teome in NCL cells.
3.3. Neural/glial co-cultures
Although in vitro models have substantially contributed to the
knowledge of the mechanisms of NCL, monolayer single cell type cul-
tures cannot fully represent the complexity of NCL pathogenesis in the
brain.
Interest in the contribution of glia to the initiation and progression
of neurodegenerative diseases has risen in recent years. Two studies to
date have isolated mixed glia and neurons from Batten disease mice and
analysed cellular function in both co-culture and isolated cultures
[112,113].
Astrocytes and microglia from CLN3 deficient mice (Cln3Δex1–6)
displayed an attenuated ability to activate in response to stimulation
alongside a modified protein secretion profile [113]. Moreover, the co-
culture of diseased neurons and PPT1 diseased astrocytes resulted in
exacerbated neuronal pathology. Conversely, co-culturing disease
neurons with healthy glial promoted neuronal survival; this indicates
that astrocytes may play a large role in neuron survival in Batten dis-
ease onset and progression. There is a similar input of glia into the
disease progression of neurons cultured from Ppt1−/− (CLN1) mice;
when diseased neurons were co-cultured with defective glia, the neu-
ronal phenotype was again significantly accelerated, and neuronal
death was elevated [112]. Likewise, when cultured with healthy glia,
the phenotype observed in neurons was ameliorated. When cultured
individually, astrocytes and microglia displayed a more activated
phenotype than healthy cells. Of note, Ppt1−/− astrocytes display ab-
normal calcium signalling and increased cytoplasmic Ca2+ levels.
Moreover, cell survival rates were decreased.
Considering that glial cells play a role in glutamate clearance in
conjunction with oxidative stress reduction in neurons, it is perhaps not
unsurprising that increased neuronal death occurs upon co-culture.
These models could prove to be useful in future as they have shown that
they recapitulate a phenotype observed in vivo; depletion of reactive
astrocytes in Ppt1−/− mice result in exacerbation of neuropathology
[114]. In Cln3Δex7/8 mouse astrocytes, Ca2+ signalling was attenuated,
and astrocyte metabolism is dysregulated despite normal levels of mi-
tochondria. Consequently, Cln3Δex7/8 neurons respond in a hyper-sen-
sitive manner indicates the significance of cell-cell interactions when
modelling NCL and other neurodegenerative disease [115].
3.4. Blood brain barrier cell models
Within the central nervous system (CNS), Cln3 is expressed in the
vascular endothelium as well as in neuronal and glial cells [96,116].
Correspondingly, abnormalities in the blood brain barrier (BBB) are
detectable in CLN3 patients. Two studies have shown autoantibodies
against CNS proteins are present in CLN3 patients' blood and mouse
models [117,118], suggesting that the BBB is compromised. A primary
cell mouse model of the BBB [119] mouse brain endothelial cells
(mBECs) express markers of adheren junctions (VE-cadherin and beta-
catenin) and tight junctions (claudin-5, occlusion and ZO1).
Tecedor et al. isolated and immortalised mBECs from Cln3+/+ and
Cln3lacz/lacz knock-in mice [120]. This study showed that CLN3 is cri-
tical for normal caveolae-dependent endocytosis via Caveolin (Cav 1),
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an essential scaffolding protein. Cln3−/− cells demonstrate abnormal
distribution of (Cav) in the plasma membrane suggesting a role for
CLN3 in anterograde trafficking of the protein. Moreover, this study
showed CLN3 alters the composition of the plasma membrane and the
trans-Golgi network and that drug reflux and cell volume modulation is
impaired when CLN3 is lost, consistent with yeast studies [120]. In
2014, Schultz et al. showed that fluid-phase endocytosis is also im-
paired in the immortalised mBECs as determined by dextran uptake
[121]. CLN3 may play a role in the deregulation of the Cdc42 activation
pathway which modulates synthesis and breakdown of actin following
fluid-phase uptake. Cao et al. also showed that fluid-phase endocytosis
was impaired in both Cln3Δex7/8 and Cln6 nclf/nclf cerebellar cells, sug-
gesting similar roles for NCL proteins in fluid-phase endocytosis across
cellular models of Batten disease [49,52,104,121].
In a follow-on study carbenoxolone (CBX) was identified, as a po-
tential therapeutic agent for CLN3 patients. CBX, a drug that blocks
hemichannels, was shown to alter lipid microdomains, normalise Cav1
signal at the plasma membrane and improve the membrane fluidity
alterations observed in Cln3−/− mBECs [122]. Moreover, CBX im-
proves Cdc42 signalling defects in Cln3 null mBECs. Although the me-
chanism is not fully understood, CBX is known to stabilise lysosomal
membranes and has shown to improve some pathological effects in
Cln3Δex7/8 mice [123,124]. CBX cannot cross the BBB; thus, its meta-
bolite, enoxolone, is most probably causing the therapeutic effect.
In summary, the murine mBEC Cln3−/− cells display a phenotype
corroborated in cerebellar cells, the models have elucidated further
understanding of a mechanism of action of CLN3 in endothelial cells,
and a potential therapy could be explored. Although mBECs do not
display a build-up lipofuscin, this might be due to cell proliferation.
However, the BBB is a complex structure, where astrocyte cell projec-
tions (“feet”) surround and provide biochemical support [125]; com-
plex cell models may be required to elucidate further the role of NCL
proteins in BBB integrity.
3.5. Induced pluripotent stem cells (iPSC)
iPSCs have been generated from wild-type and Cln1/5 double
knockout (Cln1/5ko/ko) mice and their differentiation capacity com-
pared with wild-type. Embryoid bodies (EB) differentiated from Cln1/
5ko/ko iPSC were smaller, abnormally shaped and with less differ-
entiated cells when compared to controls implying delays in differ-
entiation capacity, although no detail on cell-type distribution was
provided. These data could imply developmental impedance but re-
quire much more detailed evaluations [126].
4. Sheep cell models
Work has utilised neurons, isolated and cultured from natural sheep
models of CLN5 and CLN6 disease for ovine ceroid lipofuscinosis (OCL)
[127]. Overall, the body of work largely provided early evidence of the
accumulation of autofluorescent storage material alongside the accrual
of ATPase subunit c [127–129]. The reconstitution of CLN5 expression
also resulted in the reversal of the prolonged storage of autofluorescent
material and ATPase subunit c within the ovine neurons. Recently, the
ovine model is being utilised for pre-clinical evaluations in CLN5 gene
therapy trials as a large mammalian model, where in vitro cell models
are sure to play a significant role in establishing efficacy [130].
5. Human cell models
Much of the sub-cellular localisation and molecular biology of the
NCLs have been elucidated using human cell models, from generic
immortalised cell lines to primary and immortalised cell lines derived
from patients and most recently patient-derived induced pluripotent
stem cell (iPSC) lines. The vast majority of studies relate to late infantile
CLN2 disease and juvenile CLN3 disease, although there are some
mechanistic studies of infantile CLN1 disease.
5.1. Primary fibroblasts
While standard cell lines have provided a cellular base to study the
ectopic expression of CLN3, primary cells derived from patients with
NCLs give context to null or aberrant CLN protein expression. Dermal
fibroblasts have been widely utilised because skin biopsy has histori-
cally been included for biochemical confirmation of disease. However,
data must be contextualised in that there is no gross Batten disease
pathology in the skin. Nevertheless, some of the earliest biochemical
studies utilised patient fibroblasts to identify defects in lysosomal ac-
tivity and substrate accumulation. For example Bennett et al. first de-
scribed defects in lysosomal cathepsin activity in late-infantile and ju-
venile NCL fibroblasts [131]. The ATPase subunit c in lysosomal
substrate accumulation is described in CLN2 [132,133] and CLN3 [134]
disease fibroblasts, and has been related to cellular senescence [135]
abnormalities in fatty acid oxidation [136] and lysosomal macro-
autophagy [133]. More recently, Na+/K+-ATPase turnover at the
plasma membrane is shown to be disturbed through disruption of CLN3
interaction with Fodrin, which promotes endocytosis of the ion channel
[137].
5.2. Lymphoblasts
Patient-derived lymphoblast cells have either been employed as
primary cultures or more often immortalised to generate cell lines, for
study. Although like fibroblasts, peripheral blood derived lymphoblasts
are not directly affected by NCL disease, they are relatively easy to
source and isolate ethically. Early evaluation of lipofuscin has been
performed in CLN1, CLN2 and CLN3 patient lymphoblasts [138].
Multiple studies have described an increased sensitivity to apoptotic
stimuli in immortalised CLN3 lymphoblasts when compared to controls.
Chemotherapy-induced apoptosis has been shown to be stabilised by
reconstitution of wild-type CLN3 expression [139], resveratrol-medi-
ated reduction in ROS and ER stress [140] and fibrate treatment
maintaining mitochondrial integrity and macroautophagy [141]. Dhar
et al. observed that neurons in CLN2 and CLN3 disease could survive
through the upregulation of Bcl-2, a neuroprotective molecule. Fur-
thermore, they showed that Flupirtine (a triaminopyridine derivative
that upregulates Bcl-2) was able to rescue etoposide-induced apoptosis
in CLN1, CLN2, CLN3 and CLN6 deficient lymphoblasts [142]. Flu-
pirtine could be useful in prevention or halting the progression of NCL
disease, however more research needs to done to confirm the under-
lying mechanism of action.
5.3. Neural & glial cells
NCL genes are ubiquitously expressed throughout the body, how-
ever cells of the CNS show heightened sensitivity from the effects of
Batten disease, and currently, it is not feasible to study such patient
cells in the laboratory. Alternative approaches to studying NCLs in re-
levant cells are to obtain healthy donor CNS cells (although these are
derived from adult tissue whereas the disease is predominantly seen in
childhood, raising ethical issues) or to exploit new technologies and
generate these cell types from patient-derived induced pluripotent stem
cells (iPSC) [143]. Ghosh et al. tested the efficacy of upregulating TPP1
expression as a therapeutic approach for late infantile CLN2 disease,
where many causative mutations can result in low-level expression, by
pharmacologically agonising the PPARalpha/RXRalpha pathway [144].
They used fetal brain tissue from the Human Embryology Laboratory
(University of Washington, Seattle, USA) and purified astroglia through
long-term culture. These cells expressed functional TPP1, which could
be upregulated by the application of fibrate drugs and all-trans retinoic
acid.
The emergence of iPSC technologies provides a unique ability to
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study disease abrogation in a personalised medicine context. Archived
skin fibroblasts or peripheral blood can be used as starting material to
generate iPSC lines which can then be differentiated into neural cell
types to study the underlying biology of disease or, critically, responses
to potential therapies. To date, there have been multiple models for
NCLs derived from iPSC [145–148]. Chandrchud et al. used CLN3 iPSC-
derived neural progenitor cells (NPCs) as a follow-up to their screening
platform, further evaluating potential therapies for the treatment of
neuropathology [149]. They employed a novel biochemical assay,
screening against the accumulation of the autophagy protein LC3 by
constitutively expressing a GFP-LC3 fusion. Thapsigargin, an ER Ca2+-
ATPase inhibitor, was identified as a drug capable of increasing GFP-
LC3 puncta in CLN3Ivs13/E15 and CLN3homΔex7/8 iPSC-derived NPCs.
Similarly, Sima et al., generated three neural stem cell lines from
three patient iPSC lines, one for CLN1 and two for CLN2. Importantly,
they exhibited characteristic hallmarks of the disease phenotypes such
as enlarged lysosomes, lipid droplet accumulation and storage material
of ATPase subunit c. What was unique about their approach was that
they used this model with replacement therapy and δ-tocopherol (DT),
which was able to rescue the phenotypes. Additionally, they were able
to partially ameliorate the phenotype further with the additional use of
hydroxypropyl-β-cyclodextrin (HPBCD) [148]. This represents an im-
portant step for the use of these models for pathophysiology and drug
development.
Uusi-Rauva et al., 2017 generated CLN5Y392X iPSC lines that had the
most common CLN5 mutation [146]. These cells mimicked many of the
cellular hallmarks seen in other NCL models as well as CLN5 specific
models such as accumulation of autofluorescent material, and dis-
turbances in the lysosomal structure as seen in neuronal cells generated
from CLN3 iPSCs [145,146]. These cells will require further studies to
clarify the exact role of CLN5 and CLN3 within the endosomal/lyso-
somal systems, particularly with their common interactor protein RAB7
[150,151].
The potential for the application of NCL patient-derived iPSC in
discovery and therapy research is vast. The New York Stem Cell
Foundation (NYSCF; https://nyscf.org) in collaboration with the
Beyond Batten Disease Foundation recently announced the availability
of multiple CLN3 iPSC lines with family member controls. Equally, the
Human IPSC Initiative (HipSci; http://www.hipsci.org) in the UK has
generated a series of Batten disease iPSC lines spanning many genetic
forms of the disease. Each repository is available to academic re-
searchers worldwide.
However, with these recent advancements the lack of specific an-
tibodies that recognise NCL proteins for different species remains a
challenge to overcome [152].
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